ELDN on Nasdaq

Eledon Pharmaceuticals, Inc.

Eledon is a clinical stage biotechnology company using our immunology expertise in targeting the CD40 Ligand (“CD40L”) pathway to develop therapies to protect transplanted organs and prevent.2

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerELDN on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersIrvine, United States2
  • Incorporated inDE3
  • Business address19800 Macarthur Blvd., Suite 250, Irvine, Ca 926123
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300S17CAM13O436062
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 37829042

See how the biggest companies compare on our leaderboards

Eledon is a clinical stage biotechnology company using our immunology expertise in targeting the CD40 Ligand (“CD40L”) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (“ALS”). Our lead compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that we believe has broad therapeutic potential. We believe the central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income5678-$43.0M in 2023+168% since 2019
-$100.0M-$75.0M-$50.0M-$25.0M02019: -$16.1M-$16.1M20192020: -$18.5M-$18.5M2020+15%2021: -$36.9M-$36.9M2021+100%2022: -$88.4M-$88.4M2022+140%2023: -$43.0M-$43.0M2023−51%
Net income56791011-$45.6M in 2025+185% since 2019
-$150.0M-$100.0M-$50.0M02019: -$16.0M-$16.0M20192020: -$22.8M-$22.8M2020+42%2021: -$34.5M-$34.5M2021+51%2022: -$88.0M-$88.0M2022+155%2023: -$116.5M-$116.5M2023+32%2024: -$36.2M-$36.2M2024−69%2025: -$45.6M-$45.6M2025+26%

Every line of the income statement as filed: the last 2 fiscal years, latest first.11

Period ending2025-12-312024-12-31
Research and development$66.3M$52.0M
General and administrative$17.0M$18.6M
Total operating expenses$83.3M$70.6M
Other income, net$4.2M$3.9M
Change in fair value of warrant liabilities$33.4M$30.9M
Loss before income taxes-$45.6M-$35.8M
Provision for income taxes-$35.0K-$431.0K
Net loss-$45.6M-$36.2M
Unrealized loss on available-for-sale securities, net-$2.0K
Comprehensive loss-$45.6M-$36.2M
Basic earnings per share of common stock-$0.52-$0.66
Diluted earnings per share of common stock-$0.52-$0.66
Weighted-average common shares outstanding, basic81.8M shares48.5M shares
Weighted-average common shares outstanding, diluted81.8M shares48.5M shares

Compare Eledon Pharmaceuticals, Inc. with another company

Leadership

Who has led Eledon Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jodie Pope Morrison2014–2016
  2. Gregory J. Flesher2017–2020
  3. David-Alexandre C. Gros2020–now

President

  1. Jodie Pope Morrison2014–2016
  2. Catherine C. Turkel2017–2020
  3. Steven Perrin2022–now

Chief financial officer

  1. Lee Kalowski2014–2015
  2. Paul Sean Little2021–2025

Chief operating officer

  1. John S. McBride2014–2015
201520202025
Board members and other officers (27)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorJames Robinson named May 23, 202445

Former names

  • Novus Therapeutics, Inc.Feb 23, 2017 to Dec 22, 20203
  • Tokai Pharmaceuticals IncJun 18, 2007 to May 4, 20173

Timeline

  1. Sep 15, 2020New chief executive David-Alexandre C. Gros becomes CEO14
  2. May 11, 2017New chief executive Gregory J. Flesher becomes CEO15
  3. Sep 16, 2014New chief executive Jodie Pope Morrison becomes CEO16

Filings

209 filings to the SEC since October 2021: 8 annual reports, 17 quarterly reports, 47 major events, 66 insider forms, 28 large holders, 2 private raises, 41 other. The latest 20:

  1. Sep 4, 2026S-8 EDGAR
  2. Aug 13, 202610-Q EDGAR
  3. Aug 13, 20268-K EDGAR
  4. Aug 4, 20264 EDGAR
  5. Aug 4, 20264 EDGAR
  6. Jul 31, 2026SCHEDULE 13G EDGAR
  7. Jun 22, 20268-K EDGAR
  8. May 15, 2026SCHEDULE 13G/A EDGAR
  9. May 13, 202610-Q EDGAR
  10. May 13, 20268-K EDGAR
  11. May 11, 2026EFFECT EDGAR
  12. May 7, 2026CORRESP EDGAR
  13. May 7, 2026UPLOAD EDGAR
  14. May 1, 2026S-3 EDGAR
  15. Apr 30, 2026DEFA14A EDGAR
  16. Apr 30, 2026ARS EDGAR
  17. Apr 30, 2026DEF 14A EDGAR
  18. Apr 27, 2026SCHEDULE 13G EDGAR
  19. Apr 21, 2026PRE 14A EDGAR
  20. Mar 26, 2026SCHEDULE 13G/A EDGAR

The 209 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 4 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 9, 2024BVF INC/IL10% ownerBuy1,927,937Form 4
May 5, 2023Biotechnology Value Trading Fund OS LPBuy1,978,932Form 4
Nov 23, 2022Perrin StevenPresidentBuy1,000$2.60$2.6KForm 4
Dec 20, 2021Gros David-Alexandre CChief Executive OfficerBuy2,000$4.48$9.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. May 9, 2024Raised $50 million in a private offering of equity Form D: 24 investors so far Form D
  2. May 5, 2023Raised $35 million in a private offering of equity Form D: 38 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Bvf Inc/il6,293,282$24.8M0.6%No change
BlackRock, Inc.5,123,842$20.2M0.0%+741,597
Defilade Capital Management, L.P.3,525,338$13.9M1.9%−38,789
Vanguard Capital Management LLC3,417,223$13.5M0.0%+124,089
Goldman Sachs Group Inc2,510,308$9.9M0.0%+2,140,218
Ensign Peak Advisors, Inc2,101,224$8.3M0.0%−363,695
Geode Capital Management, LLC1,956,601$7.7M0.0%+164,818
Catalio Capital Management, LP1,695,071$6.7M1.3%+55,255
State Street Corp1,621,969$6.4M0.0%+467,298
Zimmer Partners, LP1,596,599$6.3M0.1%−278,401
Sphera Funds Management Ltd.1,191,187$4.7M0.7%−580,944
AWM Investment Company, Inc.1,100,000$4.3M0.4%No change
UBS Group AG1,048,245$4.1M0.0%+500,798
Kingdon Capital Management, L.l.c.1,039,275$4.1M0.6%No change
Millennium Management LLC979,712$3.9M0.0%New
Bank Of America Corp /de/883,097$3.5M0.0%+13,553
ADAR1 Capital Management, LLC647,812$2.6M0.1%−326,609
22nw, LP636,364$2.5M2.4%No change
Northern Trust Corp616,399$2.4M0.0%+72,557
Aqr Capital Management LLC581,028$2.3M0.0%+408,611
CM Management, LLC575,000$2.3M1.4%−75,000
Blue Owl Capital Holdings LP566,509$2.2M0.3%−853,403
Dimensional Fund Advisors LP538,738$2.1M0.0%+471,657
Vanguard Portfolio Management LLC533,365$2.1M0.0%+103,476
Vanguard Fiduciary Trust Co528,963$2.1M0.0%+25,199

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58